INHIBITION OF THE MULTIDRUG-RESISTANCE EFFLUX PUMP

被引:34
|
作者
WIGLER, PW [1 ]
PATTERSON, FK [1 ]
机构
[1] UNIV TENNESSEE, MED CTR, DEPT PATHOL, KNOXVILLE, TN 37920 USA
关键词
D O I
10.1016/0304-4157(93)90010-L
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
An ATP-dependent efflux pump is found in the plasma membrane of certain multidrug resistant (MDR) cancer cells. Drug resistance is due to decreased intracellular drug levels that have been reduced to subcytotoxic concentrations. Inhibition of the MDR efflux pump with a reversal agent may 'trap' the cytotoxic drug inside the cell; thus, cellular drug resistance is reversed. Although many different lipophilic substances exhibit reversal activity, inhibition of the pump is stereospecific with respect to the chiral agent cinchonine. In this article, several methods for the estimation of reversal potency are reviewed. Furthermore, information on the transport characteristics of reversal agents is presented. The rate equations for ATP-dependent drug efflux, competitive inhibition of the MDR pump, and noncompetitive inhibition of the pump are derived. A method is presented that discriminates between competitive or noncompetitive inhibition of the pump. These studies show the potential contribution of fundamental inhibition studies to the design of clinical reversal protocols.
引用
收藏
页码:173 / 181
页数:9
相关论文
共 50 条
  • [41] MULTIDRUG-RESISTANCE TO ANTICANCER DRUGS
    ROBERT, J
    BULLETIN DU CANCER, 1994, 81 : S33 - S38
  • [42] MULTIDRUG-RESISTANCE IN PEDIATRIC MALIGNANCIES
    CHAN, HSL
    DEBOER, G
    HADDAD, G
    GALLIE, BL
    LING, V
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1995, 9 (02) : 275 - 318
  • [43] PHARMACOLOGICAL CIRCUMVENTION OF MULTIDRUG-RESISTANCE
    FORD, JM
    HAIT, WN
    CYTOTECHNOLOGY, 1993, 12 (1-3) : 171 - 212
  • [44] ARE ESTERASES INVOLVED IN MULTIDRUG-RESISTANCE
    MARKOVIC, O
    MARKOVIC, N
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (20) : 1693 - 1693
  • [45] Immunosuppressors and reversion of multidrug-resistance
    Aouali, N
    Eddabra, L
    Macadré, J
    Morjani, H
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 56 (01) : 61 - 70
  • [46] MULTIDRUG-RESISTANCE IN HUMAN CANCER
    GOTTESMAN, MM
    GOLDSTEIN, LJ
    GALSKI, H
    PASTAN, I
    BREAST CANCER : PROGRESS IN BIOLOGY, CLINICAL MANAGEMENT AND PREVENTION, 1989, 58 : 117 - 123
  • [47] MODULATION OF MULTIDRUG-RESISTANCE - AT THE THRESHOLD
    SIKIC, BI
    JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (09) : 1629 - 1635
  • [48] MULTIDRUG-RESISTANCE IN THE LABORATORY AND CLINIC
    BELLAMY, WT
    DALTON, WS
    ADVANCES IN CLINICAL CHEMISTRY, VOL 31, 1994, 31 : 1 - 61
  • [49] A MOLECULAR MECHANISM FOR MULTIDRUG-RESISTANCE
    GOTTESMAN, MM
    CORNWELL, MM
    FOJO, AT
    CLARK, D
    UEDA, K
    RONINSON, I
    PASTAN, I
    IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY, 1987, 23 (03): : A63 - A63
  • [50] EMRR IS A NEGATIVE REGULATOR OF THE ESCHERICHIA-COLI MULTIDRUG-RESISTANCE PUMP EMRAB
    LOMOVSKAYA, O
    LEWIS, K
    MATIN, A
    JOURNAL OF BACTERIOLOGY, 1995, 177 (09) : 2328 - 2334